✦ LIBER ✦

P.5.d.002 Cannabidiol add-on usual treatment improves the outcome of patients with Parkinson's disease

✍ Scribed by Chagas, M.H.N.; Tumas, V.; Penna-Pereira, M.; Sobreira-Neto, M.; Sobreira, E.T.; Eckeli, A.L.; Hallak, J.E.C.; Dos Santos, A.C.; Crippa, J.A.S.; Zuardi, A.W.

Book ID: 121890715
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 72 KB
Volume: 23
Category: Article
ISSN: 0924-977X
DOI: 10.1016/S0924-977X(13)70868-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.5.d.001 Expression of alpha-synuclein

P.5.d.001 Expression of alpha-synuclein in patients with Parkinson's disease caused by mutations in the LRRK2 gene

✍ S. Pchelina; A. Emelianov; A. Taraskina; O. Ivanova; E. Smirnova; A. Solovieva; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

P2.123 Ropinirole prolonged release impr

P2.123 Ropinirole prolonged release improves nocturnal symptoms in patients with advanced Parkinson's disease: an analysis of grouped items on the PDSS

✍ K.R. Chaudhuri; K. Sethi; L. Giorgi; K. Rolfe; C.B. Rockett; N. Stover 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 75 KB

P2.150 Ropinirole prolonged release impr

P2.150 Ropinirole prolonged release improves nocturnal symptoms in patients with advanced Parkinson's disease: an analysis of individual items on the PDSS

✍ W. Ondo; L. Giorgi; K. Rolfe; K.R. Chaudhuri 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 58 KB

P.5.c.001 A 3-year open-label, follow-up

P.5.c.001 A 3-year open-label, follow-up study to evaluate the efficacy and tolerability of sarizotan in Parkinson's disease patients with treatment-associated dyskinesia

✍ T. Müller 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB